5:30 PM
 | 
Mar 13, 2013
 |  BC Extra  |  Financial News

Spectrum falls on lower Fusilev guidance

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) fell $4.64 (37%) to $7.79 on Wednesday after lowering its 2013 guidance for cancer drug Fusilev levoleucovorin. Spectrum said it now expects Fusilev...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >